The Health Technology
Assessment (HTA) Unit assists in the decision-making process which allows for new
medicines to be included in the Government Formulary List (GFL). The requests
for inclusion are submitted by Marketing Authorization Holders (MAHs) through
application T01 or Clinical Chairpersons through applications T02 and T02/P.
The HTA pharmacists
provide technical information on relative effectiveness and budget impact
analyses with respect to medicinal products under review. The assessment
reports are presented to the two consultative committees: the Government
Formulary List Advisory Committee (GFLAC) and the Advisory Committee for Health
Care Benefits (ACHCB).
Once a final
decision is taken by the committees, the HTA unit follows up on the decisions
as necessary. If a medicine has been recommended for approval and inclusion on
the GFL, the Central Procurement
and Supplies Unit
(CPSU) is alerted to start the procurement of the approved medicine/s.
This is followed up
with the Formulary Management Unit until formal introduction on the GFL.
